Sugi Predict

Sugi Predict / Targets / CNP

CNP

2',3'-cyclic-nucleotide 3'-phosphodiesterase · P09543 · CNP on Sugi Atlas →

0 patent compounds predicted against CNP, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CNP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs PHASE4COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure PHASE1/PHASE2COMPLETED
VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway PHASE2NOT_YET_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
CD-NP in Subjects With Stable Chronic Heart Failure PHASE1COMPLETED
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
C-Type Natriuretic Peptide and Achondroplasia nanCOMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome nanCOMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma nanUNKNOWN
Ankle Brachial Index Versus Conventional Cardiac Risk Indices nanUNKNOWN
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Pharmacodynamics of CNP During Growth Hormone Treatment nanCOMPLETED
Analysis of Cardiac Biomarker Racial Discrepancies nanENROLLING_BY_INVITATION
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CNP binder may also engage these)

ProteinNameSimilarity
P06623 — 1.000 P06623 →
Q5RFD0 — 1.000 Q5RFD0 →
P13233 — 1.000 P13233 →
P16330 — 0.998 P16330 →
F4IF36 — 0.993 F4IF36 →
SEPTIN8 Septin-8 0.993 landscape →
Q32PZ3 — 0.992 Q32PZ3 →
Q75IP6 — 0.992 Q75IP6 →
Q9SS38 — 0.991 Q9SS38 →
Q8LI34 — 0.991 Q8LI34 →
Q0E0Q3 — 0.991 Q0E0Q3 →
Q6NSW5 — 0.990 Q6NSW5 →
Q8TDB6 — 0.990 Q8TDB6 →
Q9M3B6 — 0.990 Q9M3B6 →
Q22006 — 0.990 Q22006 →
A8MVJ9 — 0.990 A8MVJ9 →
Q9D1P2 — 0.990 Q9D1P2 →
Q9R1T4 — 0.990 Q9R1T4 →
A1L2W7 — 0.990 A1L2W7 →
A4UUI3 — 0.990 A4UUI3 →
Q294E0 — 0.990 Q294E0 →
Q03460 — 0.989 Q03460 →
Q2KHP8 — 0.989 Q2KHP8 →
Q8BMD7 — 0.989 Q8BMD7 →
Q5RFL4 — 0.989 Q5RFL4 →
A7RP64 — 0.988 A7RP64 →
B6JWC1 — 0.988 B6JWC1 →
Q75CA4 — 0.988 Q75CA4 →
A8WSU9 — 0.988 A8WSU9 →
Q9ULH0 — 0.988 Q9ULH0 →